Related Experiment Video
Updated: Feb 7, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Research Priorities and Resource Allocation in the Investigation of New Drugs for Cancer in Least Developed Countries
Ricardo Eccard da Silva1,2, Angélica Amorim Amato2, Débora Dornelas Belchior Costa Andrade3
1Office of Clinical Trials, Brazilian Health Regulatory Agency (ANVISA), Setor de Indústria Trecho 5, Área Especial 57, 71205-050, Brasília, Brazil.
Abstract:
Cancer incidence has increased significantly in low- and middle-income countries. The priorities of international health research are not always aligned with the global burden of cancer. This study aims to analyze global tendencies in clinical trials in oncology and discuss research priorities and resource allocation in the investigation of new drugs for cancers that significantly affect the least developed countries. This was a retrospective and analytical study that included data collected from the World Health Organization's International Clinical Trials Registry Platform (ICTRP) in 2014. According to our results, there was a tendency for clinical trials involving breast and lung cancer to be conducted in countries with a lower level of economic development. On the other hand, cervical, stomach, and liver cancer, despite the significant burden that these place on middle- and low-income countries, were studied little among the countries selected. In conclusion, the organizations that most fund research to develop new drugs for cancer treatment continue to show little interest in prioritizing resources to fund research for certain types of cancer such as those of the cervix, stomach, and liver, which have a significant impact in low- and middle-income countries.
Insights
Global cancer research funding often overlooks high-burden cancers in low-income nations. This study highlights the need to align oncology clinical trials with the global cancer burden, particularly for understudied diseases.
Area of Science:
- Oncology
- Global Health
- Clinical Trials
Background:
- Cancer incidence is rising in low- and middle-income countries (LMICs).
- International health research priorities may not align with the global cancer burden.
- Resource allocation in oncology drug development needs examination.
Purpose of the Study:
- To analyze global trends in oncology clinical trials.
- To discuss research priorities and resource allocation for cancers affecting LMICs.
- To identify disparities in cancer drug development funding.
Main Methods:
- Retrospective and analytical study design.
- Data collected from the World Health Organization's International Clinical Trials Registry Platform (ICTRP) in 2014.
Main Results:
- Breast and lung cancer trials were more common in lower-income countries.
- Cervical, stomach, and liver cancer research was limited despite their high burden in LMICs.
- Funding disparities exist for cancer types disproportionately affecting LMICs.
Conclusions:
- Cancer research funding organizations show limited interest in prioritizing understudied, high-burden cancers in LMICs.
- There is a misalignment between global cancer burden and research investment for specific cancer types.
- Urgent reallocation of resources is needed to address neglected cancers in LMICs.
More Related Videos
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Short-distance Transport of Resources
Sustainable Development
In Vitro Drug Release Testing: Overview, Development and Validation
Xylem and Transpiration-driven Transport of Resources
Steps in Outbreak Investigation
Cancer